The effect of weight loss following 18 months of lifestyle intervention on brain age assessed with resting-state functional connectivity

  1. Gidon Levakov  Is a corresponding author
  2. Alon Kaplan
  3. Anat Yaskolka Meir
  4. Ehud Rinott
  5. Gal Tsaban
  6. Hila Zelicha
  7. Matthias Blüher
  8. Uta Ceglarek
  9. Michael Stumvoll
  10. Ilan Shelef
  11. Galia Avidan
  12. Iris Shai
  1. Ben-Gurion University of the Negev, Israel
  2. University of Leipzig, Germany
  3. Soroka Medical Center, Israel

Abstract

Background: Obesity negatively impacts multiple bodily systems, including the central nervous system. Retrospective studies that estimated chronological age from neuroimaging have found accelerated brain aging in obesity, but it is unclear how this estimation would be affected by weight loss following a lifestyle intervention.

Methods: In a sub-study of 102 participants of the DIRECT-PLUS (dietary-intervention-randomized-controlled-trial polyphenol-unprocessed) trial, we tested the effect of weight loss following 18 months of lifestyle intervention on predicted brain age based on MRI-assessed resting-state functional connectivity (RSFC). We further examined how dynamics in multiple health factors, including anthropometric measurements, blood biomarkers, and fat deposition, can account for changes in brain age.

Results: To establish our method, we first demonstrated that our model could successfully predict chronological age from RSFC in three cohorts (n=291;358;102). We then found that among the DIRECT-PLUS participants, 1% of body weight loss resulted in an 8.9 months attenuation of brain age. Attenuation of brain age was significantly associated with improved liver biomarkers, decreased liver fat, and visceral and deep subcutaneous adipose tissues after 18m of intervention. Finally, we showed that lower consumption of processed food, sweets, and beverages were associated with attenuated brain age.

Conclusions: Successful weight loss following lifestyle intervention might have a beneficial effect on the trajectory of brain aging.

Funding: The German Research Foundation (DFG), German Research Foundation - project number 209933838 - SFB 1052; B11), Israel Ministry of Health grant 87472511 (to I Shai); Israel Ministry of Science and Technology grant 3-13604 (to I Shai); and the California Walnuts Commission (to I Shai).

Clinical Trial: This trial was registered at clinicaltrials.gov as NCT03020186.

Data availability

The code for the brain age prediction model and the calculation of brain age attenuation is openly available online at https://github.com/GidLev/functional_brain_aging. The unprocessed data used for the model training and validation is openly available online at http://fcon_1000.projects.nitrc.org/indi/enhanced/neurodata.html for the eNKI dataset and available upon online access request https://camcan-archive.mrc-cbu.cam.ac.uk/dataaccess/ for the CamCAN dataset. Data from the DIRECT-PLUS trial is not publicly available since it contains information that could compromise the privacy of research participants. However, de-identified data could be shared upon request, subject to approval from the Soroka Medical Center Medical Ethics Board. A processed version of the data that includes participants' demographics, predicted and observed age and weight values for T0 and T18 is available as supplementary information.

The following previously published data sets were used
    1. Nooner
    2. KB
    3. Colcombe
    4. SJ
    5. Tobe
    6. RH
    7. Mennes
    8. M
    9. Benedict
    10. MM
    11. Moreno
    12. AL
    13. Panek
    14. LJ
    15. Brown
    16. S
    17. Zavitz
    18. ST
    19. Li
    20. Q and Sikka
    21. S
    (2012) The NKI-Rockland sample
    Wide array of physiological and psychological assessments, genetic information, and advanced neuroimaging.

Article and author information

Author details

  1. Gidon Levakov

    Department of Cognitive and Brain Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    For correspondence
    gidonle@post.bgu.ac.il
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5520-3556
  2. Alon Kaplan

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  3. Anat Yaskolka Meir

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  4. Ehud Rinott

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  5. Gal Tsaban

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  6. Hila Zelicha

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  7. Matthias Blüher

    Department of Medicine, University of Leipzig, Leipzig, Germany
    Competing interests
    Matthias Blüher, has received consulting fees from Amgen, Astra Zeneca, Boehringer-Ingelheim, Bayer, Lilly, Novo Nordisk, Novartis, Sanofi and Pfizer; and fees for lectures/ presentations from Amgen, Astra Zeneca, Boehringer-Ingelheim, Bayer, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, Sanofi and Pfizer. The author is also on the advisory board for Boehringer-Ingelheim. The author has no other competing interests to declare..
  8. Uta Ceglarek

    Department of Medicine, University of Leipzig, Leipzig, Germany
    Competing interests
    No competing interests declared.
  9. Michael Stumvoll

    Department of Medicine, University of Leipzig, Leipzig, Germany
    Competing interests
    No competing interests declared.
  10. Ilan Shelef

    Department of Diagnostic Imaging, Soroka Medical Center, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  11. Galia Avidan

    Department of Psychology, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2293-3859
  12. Iris Shai

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.

Funding

The German Research Foundation (209933838 SFB 1052; B11)

  • Iris Shai

Israel Ministry of Health (grant 87472511)

  • Iris Shai

Israel Ministry of Science and Technology (3-13604)

  • Iris Shai

California Walnuts Commission

  • Iris Shai

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This work was based on a sub-study of the DIREC-PLUS trial (clinicaltrials.gov ID: NCT03020186). The Soroka Medical Center Medical Ethics Board and Institutional Review Board provided ethics approval. All participants provided written consent and received no financial compensation.

Copyright

© 2023, Levakov et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 7,301
    views
  • 724
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gidon Levakov
  2. Alon Kaplan
  3. Anat Yaskolka Meir
  4. Ehud Rinott
  5. Gal Tsaban
  6. Hila Zelicha
  7. Matthias Blüher
  8. Uta Ceglarek
  9. Michael Stumvoll
  10. Ilan Shelef
  11. Galia Avidan
  12. Iris Shai
(2023)
The effect of weight loss following 18 months of lifestyle intervention on brain age assessed with resting-state functional connectivity
eLife 12:e83604.
https://doi.org/10.7554/eLife.83604

Share this article

https://doi.org/10.7554/eLife.83604

Further reading

    1. Epidemiology and Global Health
    2. Genetics and Genomics
    Rashmi Sukumaran, Achuthsankar S Nair, Moinak Banerjee
    Research Article

    Burden of stroke differs by region, which could be attributed to differences in comorbid conditions and ethnicity. Genomewide variation acts as a proxy marker for ethnicity, and comorbid conditions. We present an integrated approach to understand this variation by considering prevalence and mortality rates of stroke and its comorbid risk for 204 countries from 2009 to 2019, and Genome-wide association studies (GWAS) risk variant for all these conditions. Global and regional trend analysis of rates using linear regression, correlation, and proportion analysis, signifies ethnogeographic differences. Interestingly, the comorbid conditions that act as risk drivers for stroke differed by regions, with more of metabolic risk in America and Europe, in contrast to high systolic blood pressure in Asian and African regions. GWAS risk loci of stroke and its comorbid conditions indicate distinct population stratification for each of these conditions, signifying for population-specific risk. Unique and shared genetic risk variants for stroke, and its comorbid and followed up with ethnic-specific variation can help in determining regional risk drivers for stroke. Unique ethnic-specific risk variants and their distinct patterns of linkage disequilibrium further uncover the drivers for phenotypic variation. Therefore, identifying population- and comorbidity-specific risk variants might help in defining the threshold for risk, and aid in developing population-specific prevention strategies for stroke.

    1. Epidemiology and Global Health
    2. Evolutionary Biology
    Renan Maestri, Benoît Perez-Lamarque ... Hélène Morlon
    Research Article

    Several coronaviruses infect humans, with three, including the SARS-CoV2, causing diseases. While coronaviruses are especially prone to induce pandemics, we know little about their evolutionary history, host-to-host transmissions, and biogeography. One of the difficulties lies in dating the origination of the family, a particularly challenging task for RNA viruses in general. Previous cophylogenetic tests of virus-host associations, including in the Coronaviridae family, have suggested a virus-host codiversification history stretching many millions of years. Here, we establish a framework for robustly testing scenarios of ancient origination and codiversification versus recent origination and diversification by host switches. Applied to coronaviruses and their mammalian hosts, our results support a scenario of recent origination of coronaviruses in bats and diversification by host switches, with preferential host switches within mammalian orders. Hotspots of coronavirus diversity, concentrated in East Asia and Europe, are consistent with this scenario of relatively recent origination and localized host switches. Spillovers from bats to other species are rare, but have the highest probability to be towards humans than to any other mammal species, implicating humans as the evolutionary intermediate host. The high host-switching rates within orders, as well as between humans, domesticated mammals, and non-flying wild mammals, indicates the potential for rapid additional spreading of coronaviruses across the world. Our results suggest that the evolutionary history of extant mammalian coronaviruses is recent, and that cases of long-term virus–host codiversification have been largely over-estimated.